GlassScriptPhysician profile
Julia Mcaree
NPI 1053926899
$10,854.47
in general payments reported to CMS, 2019-2025
57 companies · $2,590 in 2025
The $2,590 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,856 · 2022: $2,358 · 2023: $2,187 · 2024: $1,864 · 2025: $2,590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,351 · Education: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,350.83 |
| Education | $289.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,729.76 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,449.27 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $978.26 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Lilly USA, LLC | $660.38 | 2021-2024 | Mounjaro, Taltz, Olumiant |
| Genzyme Corporation | $624.16 | 2021-2025 | |
| Pfizer INC. | $527.92 | 2021-2025 | |
| Novo Nordisk INC | $402.84 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Biotech, INC. | $392.29 | 2021-2023 | Tremfya, Simponi Aria, Remicade |
| Amgen INC. | $382.38 | 2021-2024 | Otezla, Repatha, Enbrel |
| Glaxosmithkline, LLC. | $320.51 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $319.55 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $287.49 | 2021-2025 | Dupixent |
| Leo Pharma INC. | $180.25 | 2021-2025 | Adbry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.40 | 2021-2025 | Jardiance, Spevigo, Ofev |
| Ucb, INC. | $164.83 | 2022-2025 | Nayzilam, Bimzelx, Cimzia |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Mcaree listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.